Labcorp Holdings Inc（LH）財務資料LHLabcorp Holdings Inc

Labcorp Holdings Inc. (LH) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is DX, accounting for 78.1% of total sales, equivalent to $2.76B. Other significant revenue streams include BLS and Intercompany eliminations. Understanding this composition is critical for investors evaluating how LH navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Labcorp Holdings Inc. maintains a gross margin of 27.71%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 12.24%, while the net margin is 8.02%. These profitability ratios, combined with a Return on Equity (ROE) of 11.74%, provide a clear picture of how effectively LH converts its operational activities into shareholder value.

In the context of the broader market, LH competes directly with industry leaders such as PHG and SOLV. With a market capitalization of $24.99B, it holds a leading position in the sector. When comparing efficiency, LH's gross margin of 27.71% stands against PHG's 49.31% and SOLV's 58.62%. Such benchmarking helps identify whether Labcorp Holdings Inc. is trading at a premium or discount relative to its financial performance.

The company's gross margin is strong at 27.71% for Q2 2026, and it has demonstrated consistent revenue growth, with Q2 2026 revenue reaching $3.73 billion, up from $3.52 billion in Q2 2025.